Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043400 | 1.00 | PSMB5 (0.56) | PSMB5SLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL5870279 | 0.91 | PPARG (0.55) | PSMB5CYP1A2CYP2C9CYP2C19SRR | |
| SCHEMBL6061437 | 0.89 | SLC1A3 (0.48) | PSMB5SLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL8496632 | 0.85 | PSMB5 (0.55) | PSMB5CTSKALDH1A1 | |
| SCHEMBL7541726 | 0.85 | PPARG (0.63) | PSMB5ALDH1A1PPARGPPARA | |
| SCHEMBL7541731 | 0.85 | PPARG (0.63) | PSMB5ALDH1A1PPARGPPARA | |
| SCHEMBL4704738 | 0.85 | MME (0.47) | PSMB5CTSKPPARGPPARAPPARD | |
| SCHEMBL7545793 | 0.84 | LDHA (0.53) | CTSKPPARGPPARAPPARD | |
| SCHEMBL7545786 | 0.84 | LDHA (0.53) | CTSKPPARGPPARAPPARD | |
| SCHEMBL4449480 | 0.83 | NR4A2 (0.47) | PSMB5MEN1KMT2APPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5163221-A | — | — | None | — | — | JP | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| EP-1209147-A1 | CARBOXYLIC ACID DERIVATIVES AND ADHESION MOLECULE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2002-05-29 | — | — | EP | disclosed |
| US-6153171-A | Methods for identifying compounds effective for treating neurodegenerative disorders and for monitoring the therapeutic intervention therefor | SIBIA NEUROSCIENCES, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| US-5962419-A | NERVOUS SYSTEM DISORDERS; BRAIN DISORDERS | SIBIA NEUROSCIENCES, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5872101-A | Methods of treating neurodegenerative disorders using protease inhibitors | SIBIA NEUROSCIENCES, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5863902-A | Methods of treating neurodegenerative disorders using protease inhibitors | SIBIA NEUROSCIENCES, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5804560-A | MODULATES PROCESSING OF AMYLOID PRECURSOR PROTEIN | SIBIA NEUROSCIENCES, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5714471-A | USEFUL IN INDICATING NEURODEGENERATIVE DISORDERS CHARACTERIZED BY DEPOSITION OF CEREBRAL AMYLOID | SIBIA NEUROSCIENCES, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0800528-A1 | PEPTIDE AND PEPTIDE ANALOG PROTEASE INHIBITORS | Sibia Neurosciences, Inc. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020725-A2 | PEPTIDE, PEPTIDE ANALOG AND AMINO ACID ANALOG PROTEASE INHIBITORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996020949-A1 | PEPTIDE AND PEPTIDE ANALOG PROTEASE INHIBITORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-07-11 | — | — | WO | disclosed |
| JP-H05163221-A | OXY ACID DERIVATIVE | FUJIREBIO INC | 1993-06-29 | — | — | JP | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | PSMB5 180/4885SLC1A3 4132/4885SLC1A2 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.